Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSPI and Unilever's Take Control

This article was originally published in The Tan Sheet

Executive Summary

Consumer organization is "concerned" FDA conducted review of the cholesterol-lowering margarine "in secret" and "did not provide the public an opportunity to comment." FDA cleared the product April 30 ("The Tan Sheet" May 10, p. 13). CSPI also notes June 5 that if FDA had considered the product's labeled statement of cholesterol benefit to be a health claim, "the agency would have been legally required to give the public an opportunity to comment before the product was placed on the market." FDA has "prohibited health claims for heart disease on foods, like margarine, that are not low in fat," the watchdog group notes. "FDA has excluded the public from the decision-making process and let the company skirt the rules," CSPI says
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel